Daiichi Sankyo and Ranbaxy announce synergy in Brazil

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Daiichi Sankyo and Ranbaxy announce synergy in Brazil

Genéricos/Novedades | Posted 29/04/2013 0 Post your comment

India-based Ranbaxy Laboratories (Ranbaxy) and its Japanese parent company Daiichi Sankyo announced on 17 April 2013 plans to integrate their generic and brand-name drug business operations in Brazil.

As part of the collaboration, Ranbaxy will support Daiichi Sankyo’s Brazilian subsidiary, Daiichi Sankyo Brasil Farmaceutica (Daiichi Sankyo Brazil), to enter the branded generics market, in addition to its established business of providing innovative products.

In Brazil, Daiichi Sankyo has built up its market presence with innovative pharmaceuticals through Daiichi Sankyo Brazil. Ranbaxy, on the other hand, has become a prominent player in the Brazilian generics market through its subsidiary, Ranbaxy Farmaceutica. The plan is for Ranbaxy Farmaceutica to continue to independently promote Ranbaxy’s generics and also enter into branded generics in Brazil.

Brazil currently represents the largest pharmaceutical market in Latin America and it is expected to become the fourth biggest market in the world in 2016. Generics were first commercialized in Brazil in 1999, and in 2011 generics made up 20.6% of Brazilian pharmaceutical industry sales.

The Daiichi Sankyo Group expects this synergy to expand its presence in Brazil through its hybrid business model promoting innovative drugs, branded generics and generics.

Ranbaxy became a part of the Daiichi Sankyo Group in October 2008 after Japan’s third largest drugmaker bought a majority stake for Rs 22,000 crore [1]. Earlier in 2013 the two companies also integrated their business operations in Thailand.

Related articles

Ranbaxy gets FDA approval and launches generic atorvastatin

Daiichi Sankyo pursues a global strategy

Reference

1. GaBI Online - Generics and Biosimilars Initiative. Ranbaxy to transfer R & D and focus on generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Apr 29]. Available from: www.gabionline.net/Pharma-News/Ranbaxy-to-transfer-R-D-and-focus-on-generics

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Ranbaxy